Article

Allergan appoints Douglas Ingram as president

Allergan Inc. has named Douglas S. Ingram as the company’s new president. Ingram will lead the company’s global commercial operations, with responsibility for its broad portfolio of pharmaceutical, consumer, and medical device products.

Irvine, CA-Allergan Inc. has named Douglas S. Ingram as the company’s new president. Ingram will lead the company’s global commercial operations, with responsibility for its broad portfolio of pharmaceutical, consumer, and medical device products.

With more than 25 years of experience, Ingram has a strong background in the health-care industry, both in the United States and internationally. For the past 3 years, Ingram has served as executive vice president and president for Europe, Africa, and Middle East with Allergan. In this role, he was responsible for its regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, development, and general management.

Ingram also served as executive vice president and chief administrative officer, and at various times during his career, he led Allergan’s global legal affairs, compliance, internal audit and internal controls, human resources, regulatory affairs and safety, and global corporate affairs and public relations departments.

“During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business,” said David E.I. Pyott, chairman of the board and chief executive officer of Allergan. “Doug has built an impressive record of accomplishment and is widely regarded throughout our organization as a leader who is committed to the highest standards of excellence in all areas. I am confident that his broad range of commercial and functional experiences will serve him well as he assumes this new and important role.”

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.